U of T study shows barriers to HIV vaccine acceptance

July 18, 2005

Public health officials must be sensitive to concerns about stigma and fear of vaccine-induced infection if they want women to take advantage of HIV vaccines now under development, says a University of Toronto researcher.

"The first generation of HIV vaccines may be available within 10 years but availability doesn't guarantee uptake," says U of T social work professor Peter A. Newman, one of the authors of a study in the June AIDS Education and Prevention. "Health-care officials must begin preparing now to address the social, behavioural and biological barriers they are likely to encounter in disseminating a future vaccine."

Through a series of focus groups with both health-care providers and women from at-risk populations in Los Angeles, Newman and colleagues from the University of California at Los Angeles and the Los Angeles County Health Department identified barriers to future HIV vaccine acceptance. In addition to worries about being labelled gay or promiscuous if they are vaccinated and fear of contracting HIV/AIDS from the vaccine, women in the focus groups were also concerned about power dynamics (the influence of husbands who are in denial about their own risk behaviours), affordability, reproductive side effects and discrimination in obtaining the vaccine.

However, the women also identified some strong motivations for getting vaccinated. Many viewed it as empowering to be able to protect themselves against HIV infection and others were eager to ensure their children were also protected. Both women and providers suggested that the vaccine be delivered as part of routine care so women would be able to take advantage of its protection without having to confront their partners and wouldn't have the stigma of obtaining care from HIV-identified services.

"These are all important factors to consider when a future vaccine is rolled out," says Newman. "Vaccines must be easy to obtain and affordable and women's particular concerns must be addressed or HIV vaccines will have limited success among the people most vulnerable to infection."

University of Toronto

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.